Purchase of Rats for continuation of E0301101: Perinatal CNS Activinty and PK Br
Forecast New Requirement Updated
- Agency
-
Food and Drug Administration
Department of Health and Human Services
- Solicitation expected
- Not on record
- Estimated value
- $10,000 to $25,000
- Set-aside
- No set-aside
Forecast facts
- Anticipated award
- NAICS code
- 112990 All Other Animal Production
- Points of contact
-
- NCTR Acquisition Liaison nctracquisitions@fda.hhs.gov
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The Food and Drug Administration is procuring rats for continuation of study E0301101 on perinatal central nervous system activity and pharmacokinetics, with estimated award on 2026-03-01. The purchase supports Aims 2 and 3 of the research, which will employ MALDI mass spectrometry imaging to assess cannabidiol (CBD) and CBD metabolite distribution in animal tissues using dose parameters established in Aim 1, completed in early 2026.
The estimated award value ranges from $10,000 to $25,000. The requirement is for one set of rats to complete the imaging and distribution analysis work. Questions regarding this requirement should be directed to the FDA Acquisition Liaison at nctracquisitions@fda.hhs.gov.
Forecast text
Purchase of rats for CBD animal study: This is a continuation of E0301101. Aim 1 of the study was a PK/dose range study and was completed in early 2026. Aims 2 and 3 will on require one set of animals which is this PO to utilize MALDI MSI to assess CBD and CBD metabolite distribution using the doses found in aim 1.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast